77 related articles for article (PubMed ID: 32174259)
1. Comparative modeling and structure based drug repurposing of PAX2 transcription factor for targeting acquired chemoresistance in pancreatic ductal adenocarcinoma.
Aier I; Semwal R; Raj U; Varadwaj PK
J Biomol Struct Dyn; 2021 Apr; 39(6):2071-2078. PubMed ID: 32174259
[TBL] [Abstract][Full Text] [Related]
2. An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.
Aier I; Semwal R; Dhara A; Sen N; Varadwaj PK
PLoS One; 2019; 14(10):e0223554. PubMed ID: 31622355
[TBL] [Abstract][Full Text] [Related]
3. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Adamska A; Falasca M
World J Gastroenterol; 2018 Aug; 24(29):3222-3238. PubMed ID: 30090003
[TBL] [Abstract][Full Text] [Related]
4.
Aier I; Semwal R; Sharma A; Varadwaj PK
J Biomol Struct Dyn; 2021 Aug; 39(13):4893-4901. PubMed ID: 32579088
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas.
Gnemmi V; Leroy X; Triboulet JP; Pruvot FR; Villers A; Leteurtre E; Buob D
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):157-62. PubMed ID: 24344503
[TBL] [Abstract][Full Text] [Related]
6. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
7. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
Sasaki N; Ishiwata T; Hasegawa F; Michishita M; Kawai H; Matsuda Y; Arai T; Ishikawa N; Aida J; Takubo K; Toyoda M
Cancer Sci; 2018 Apr; 109(4):1135-1146. PubMed ID: 29444383
[TBL] [Abstract][Full Text] [Related]
8. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
[TBL] [Abstract][Full Text] [Related]
9. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.
Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S
Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532
[No Abstract] [Full Text] [Related]
10. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
11. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
12. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma.
Altan B; Kaira K; Watanabe A; Kubo N; Bao P; Dolgormaa G; Bilguun EO; Araki K; Kanai Y; Yokobori T; Oyama T; Nishiyama M; Kuwano H; Shirabe K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):141-153. PubMed ID: 29149426
[TBL] [Abstract][Full Text] [Related]
13. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
14. NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Kim EJ; Kim YJ; Lee HI; Jeong SH; Nam HJ; Cho JH
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629871
[TBL] [Abstract][Full Text] [Related]
15. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
17. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
Logsdon DP; Grimard M; Luo M; Shahda S; Jiang Y; Tong Y; Yu Z; Zyromski N; Schipani E; Carta F; Supuran CT; Korc M; Ivan M; Kelley MR; Fishel ML
Mol Cancer Ther; 2016 Nov; 15(11):2722-2732. PubMed ID: 27535970
[TBL] [Abstract][Full Text] [Related]
18. MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.
Xu C; Qi X
J Clin Lab Anal; 2020 Oct; 34(10):e23442. PubMed ID: 32592206
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
20. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
